Choosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin?

scientific article published on 2 September 2008

Choosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin? is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/NCPONC1215
P698PubMed publication ID18762793

P50authorLinda T VahdatQ40149511
P2860cites workPostoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.Q33377581
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerQ34601123
Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancerQ36614607
Weekly paclitaxel in the adjuvant treatment of breast cancer.Q37346811
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trialsQ46828225
HER2 and Response to Paclitaxel in Node-Positive Breast CancerQ57578418
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and LeuQ57578575
P433issue10
P304page(s)570-571
P577publication date2008-09-02
P1433published inNature Clinical Practice OncologyQ15752073
P1476titleChoosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin?
P478volume5

Reverse relations

cites work (P2860)
Q34274152GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy
Q36825817Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature

Search more.